Back to potential offers, there could be a clause that Amgen has the first right as they use their CD19. Maybe that stops others at this stage. But we can ask as well, if Amgen is in the loop, why haven't they made a move if the early results are so fantastic. Or would IMU have to do trial again if another CD19 brand would be used? That way Amgen would be protected from missing out.
So much speculation, IMU could let us know a lot more, I think.
GLTA
IMU Price at posting:
2.9¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)